Video Experimental Relacionado
Updated: Jul 14, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Inducción de la caquexia en ratones mediante la administración sistémica de miostatina
Teresa A Zimmers1, Monique V Davies, Leonidas G Koniaris
1Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.
Science (New York, N.Y.)
|May 25, 2002
Resumen
La miostatina normalmente suprime el crecimiento muscular. En ratones adultos, la miostatina actúa sistémicamente, causando pérdida de músculo y grasa, y puede ser un objetivo para el tratamiento de enfermedades de pérdida muscular.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Fisiología Fisiología Fisiología.
- Genética La genética.
Sus antecedentes:
- Las deficiencias genéticas en miostatina conducen a un aumento de la masa muscular esquelética en ratones y ganado.
- La miostatina es un supresor conocido del crecimiento muscular.
- El momento del efecto de la miostatina (prenatal vs. postnatal) en la masa muscular no está claro.
Objetivo del estudio:
- Para investigar el papel sistémico de la miostatina en animales adultos.
- Para determinar si la actividad de la miostatina puede ser modulada en ratones adultos.
- Para explorar la miostatina como un objetivo terapéutico potencial para las condiciones de desgaste muscular.
Principales métodos:
- Evaluación de la forma circulante y la activación de la miostatina en ratones adultos.
- Inducción de la sobreexpresión sistémica de miostatina en ratones adultos.
- Observando los efectos de la sobreexpresión de la miostatina en la masa muscular y grasa.
Principales resultados:
- La miostatina circula en forma latente en ratones adultos, activada por el ácido.
- La sobreexpresión sistémica de miostatina en ratones adultos causó una pérdida significativa de músculo y grasa.
- Los efectos observados imitaban los síndromes de caquexia humana.
Conclusiones:
- La miostatina actúa sistémicamente en animales adultos.
- La miostatina es un regulador clave de la masa muscular y grasa después del parto.
- La miostatina presenta un objetivo farmacológico potencial para afecciones que implican pérdida muscular, como la caquexia.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:25Cholinergic Receptors: Muscarinic
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:28Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...